WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Four Astronauts From Four Countries Return to Earth After Six Months in OrbitAi Weiwei mourns Hong Kong freedoms but is 'proud' of Tiananmen middleNew Zealand joins 50 countries in condemning transfer of weapons between North Korea and RussiaJapan's lunar craft lands successfully but can't generate solar powerDeath penalty for artist behind Kyoto anime fire, which killed 36ACT leader David Seymour laments 'lost decades' as coalition gets to workScreening of Hong Kong Poly U siege documentary slammed by proTame Iti brings Haki Ātea to WaitangiChinese TV authorities move to curb obsessive fan cultureAi Weiwei mourns Hong Kong freedoms but is 'proud' of Tiananmen middle
2.4727s , 6503.15625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Perspective news portal